Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emergency medicine pharmacotherapy compromises accuracy of plasma creatinine determination by enzyme-based methods: real-world clinical evidence and implications for clinical practice.
Demlova R, Kozakova S, Rihacek M, Buckova D, Horska K, Wiewiorka O, Boucek L, Selingerova I, Podborska M, Korberova A, Mikuskova A, Starha J, Benovska M, Radina M, Richter M, Zdrazilova Dubska L, Valik D. Demlova R, et al. Among authors: valik d. Front Med (Lausanne). 2024 Jan 8;10:1236948. doi: 10.3389/fmed.2023.1236948. eCollection 2023. Front Med (Lausanne). 2024. PMID: 38259831 Free PMC article.
Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors.
Vejmelkova K, Pokorna P, Noskova K, Faustmannova A, Drabova K, Pavelka Z, Bajciova V, Broz M, Tinka P, Jezova M, Palova H, Kren L, Valik D, Slaby O, Sterba J. Vejmelkova K, et al. Among authors: valik d. Sci Rep. 2023 Dec 7;13(1):21623. doi: 10.1038/s41598-023-48774-2. Sci Rep. 2023. PMID: 38062114 Free PMC article.
Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.
Pokorna P, Lakka Klement G, Vasikova A, Kanderova V, Jezova M, Noskova K, Mudry P, Kyr M, Merta T, Bajciova V, Krenova Z, Palova H, Valik D, Zdrazilova Dubska L, Slaby O, Sterba J. Pokorna P, et al. Among authors: valik d. JCO Precis Oncol. 2022 Jun;6:e2100525. doi: 10.1200/PO.21.00525. JCO Precis Oncol. 2022. PMID: 35700412 Free PMC article. No abstract available.
Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.
Hacker UT, Hasenclever D, Baber R, Linder N, Busse H, Obermannova R, Zdrazilova-Dubska L, Valik D, Lordick F. Hacker UT, et al. Among authors: valik d. Ann Oncol. 2022 Jul;33(7):685-692. doi: 10.1016/j.annonc.2022.03.274. Epub 2022 Apr 5. Ann Oncol. 2022. PMID: 35395383 Free article. Clinical Trial.
N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer.
Zahradnikova M, Ihnatova I, Lattova E, Uhrik L, Stuchlikova E, Nenutil R, Valik D, Nalezinska M, Chovanec J, Zdrahal Z, Vojtesek B, Hernychova L, Novotny MV. Zahradnikova M, et al. Among authors: valik d. J Proteomics. 2021 Jan 6;230:103964. doi: 10.1016/j.jprot.2020.103964. Epub 2020 Sep 6. J Proteomics. 2021. PMID: 32898699
89 results